What happens if a sponsor misclassifies a UADE as a routine adverse event?

Misclassification undermines the entire safety oversight structure of the study: it delays IRB awareness of a potentially serious new risk, can prevent timely study modifications or subject protections, and is a common finding in FDA bioresearch monitoring inspections. Because IRBs have authority to suspend or terminate a study based on UADE reports, failing to escalate correctly can also expose the sponsor to enforcement action and jeopardize the integrity and credibility of the entire clinical dataset.

Who has the final authority to determine whether an event is a UADE?

While investigators make the initial determination and report to the sponsor, the sponsor is responsible for independently evaluating each report and making the final classification decision before it reports to FDA and IRBs, typically through a documented medical monitor review process. Sponsors should maintain clear written criteria distinguishing UADEs from anticipated events so that classification decisions are consistent across sites and defensible during an inspection.

All terms

Clinical & TrialsClinical Evidence Post-Market & Safety Startup LifecycleUADE

Unanticipated Adverse Device Effect

Q: What are the exact reporting timelines for a UADE under 21 CFR 812?

The investigator who identifies a UADE must report it to the sponsor and to the reviewing IRB within 10 working days under 21 CFR 812.46. The sponsor must then evaluate the report and, if the effect is confirmed as a UADE, notify FDA and all reviewing IRBs as soon as possible but no later than 10 working days after first learning of the effect, per 21 CFR 812.150(b)(1). These reports go through the IDE supplement framework to CDRH, not through the MDR Form 3500A pathway used for post-market adverse events.

Any serious adverse effect on health or safety in an IDE study not previously identified in the investigational plan, triggers strict reporting timelines.

Reviewed by Christian Espinosa, Founder, Blue Goat CyberLast reviewed June 20, 2026

Definition

An Unanticipated Adverse Device Effect (UADE) is, per 21 CFR 812.3(s), any serious adverse effect on health or safety, any life-threatening problem, or death caused by, or associated with, an investigational device, if that effect was not previously identified in nature, severity, or degree of incidence in the investigational plan or application, or any other unanticipated serious problem associated with the device that relates to the rights, safety, or welfare of subjects. UADEs trigger specific reporting obligations: investigators report to the sponsor and IRB within 10 working days; sponsors report to FDA and all reviewing IRBs as soon as possible but no later than 10 working days after first learning of the effect.

What the regulation says

21 CFR 812.3(s) defines UADE; 21 CFR 812.46 governs investigator reporting; 21 CFR 812.150(b)(1) governs sponsor reporting. FDA Form 3500A is not used for UADEs (that's for MDR post-market reports), UADE reports are submitted to CDRH per the IDE supplement framework.

What this means in practice

UADE determinations are a defining sponsor responsibility in any IDE-conducted clinical investigation. Misclassification, calling a UADE a routine adverse event, or vice versa, has cascading consequences: IRB suspension authority, FDA enforcement, study integrity. Sponsors maintain a UADE classification process with medical monitor oversight and clear criteria distinguishing UADEs from anticipated adverse events listed in the Investigator Brochure.

Examples

A patient in a clinical trial for a novel implantable glucose sensor develops a severe, systemic allergic reaction leading to anaphylaxis, a complication not mentioned in the investigational plan or known adverse events.
During a study of a new catheter-based atrial fibrillation ablation system, several patients experience unanticipated, significant damage to adjacent esophageal tissue, a severity of injury not foreseen or described in the study protocol.
An investigational surgical robot used for spinal fusion procedures causes unexpected and reproducible nerve damage in a specific limb, an adverse effect not previously identified in preclinical testing or early human studies.

Common pitfalls

•Treating any serious adverse event as a UADE, UADEs require the 'unanticipated' criterion plus device association.
•Missing the 10-working-day clocks, investigator-to-sponsor and sponsor-to-FDA/IRBs both have hard timelines.
•Failing to update the Investigator Brochure after a UADE is determined, subsequent occurrences of the same effect may no longer qualify as unanticipated.

Frequently asked questions

A UADE is a serious adverse effect on health or safety, a life-threatening problem, death, or another serious problem affecting subject rights, safety, or welfare that was not previously identified in nature, severity, or incidence in the investigational plan or application. An anticipated adverse event, by contrast, is one already described with its expected nature and frequency in the Investigator Brochure or investigational plan, so it does not trigger the same expedited reporting pathway. The determination depends entirely on what the Investigator Brochure and protocol already disclosed as expected, which is why that baseline document must be precise and current.

Grouped by theme

Editor's picks

· Hand-selected related concepts

Clinical & Trials

Adverse Event(AE)

Any untoward medical occurrence in a subject, whether or not related to the device.

Clinical & Trials

IDE Annual Progress Report

Annual report sponsors must submit to FDA summarizing the progress of an approved IDE study, including enrollment, deviations, and adverse events.

Clinical & Trials

IDE Supplement

Amendment to an approved Investigational Device Exemption for protocol or device changes.

Clinical & Trials

Informed Consent

Voluntary, informed agreement to participate in research after disclosure of risks and benefits.

More in Clinical & Trials

· Same category

Clinical & Trials

Institutional Review Board(IRB)

Board that reviews and approves human-subjects research at an institution.

Clinical & Trials

Investigational Device Exemption(IDE)

FDA authorization to use an investigational device in a clinical study.

Clinical & Trials

Investigator Brochure(IB)

Compilation of clinical and nonclinical information on an investigational device given to clinical investigators, establishes what's 'anticipated' for UADE determinations.

Clinical & Trials

Serious Adverse Event(SAE)

Adverse event resulting in death, life-threat, hospitalization, persistent disability, or congenital anomaly.

Cited by

Where this term appears across MedTech Terms.

Ecosystems (3)

Latest in MedTech

Sources

3 sources

Every citation below opens the original document. Each is graded against our source-tier hierarchy so you can see what rests on binding law versus commentary.

Tier 1Binding law and standards· 2Tier 2Regulator guidance and consensus· 1

Link health: 3 verified· last checked 2026-06-20

eCFR·2ICH·1

Inline markers like [1] jump to the matching reference above.

My progress

All terms0 / 513

Clinical & Trials0 / 52

Saved on this device, and to your account when signed in. View studied terms

Full glossary

Browse all terms A to Z, each with a short definition.

On this term

Category: Clinical & Trials
Acronym: UADE
Sources: 3
Updated: 6/20/2026

Compare with another term

Learn in 60 seconds

Any serious adverse effect on health or safety in an IDE study not previously identified in the investigational plan, triggers strict reporting timelines.

·UADE determinations are a defining sponsor responsibility in any IDE-conducted clinical investigation.
·Misclassification, calling a UADE a routine adverse event, or vice versa, has cascading consequences: IRB suspension authority, FDA enforcement, study integrity.
·Sponsors maintain a UADE classification process with medical monitor oversight and clear criteria distinguishing UADEs from anticipated adverse events listed in the Investigator Brochure.

Remember this

Watch out: Treating any serious adverse event as a UADE, UADEs require the 'unanticipated' criterion plus device association.

Related terms

You may also need

Auto-suggested from Clinical & Trials and shared keywords.

All Clinical & Trials terms

From the Blue Goat network

Related resources and services on this topic.

MedTech Launchpad
MedTech funding rounds, accelerators, and launch resources.